Innovotech Inc.
TSX VENTURE : IOT

Innovotech Inc.

October 23, 2008 06:00 ET

Innovotech Diagnostic Kit Shows Positive Results in Clinical Setting

EDMONTON, ALBERTA--(Marketwire - Oct. 23, 2008) - Innovotech Inc. (TSX VENTURE:IOT):

Dr. Neil Brown, Director of the Cystic Fibrosis Clinic at the University of Alberta Hospital in Edmonton will present results of a clinical evidence trial of bioFILM PA™, at the North American Cystic Fibrosis Conference in Orlando, October 23-25, 2008. The data gathered by Dr. Brown shows an increase in lung function in a significant number of patients, an important measurement of the well-being of patients with Cystic Fibrosis.

"The information developed through our partnership with Dr. Brown, while limited in scope, indicates a role for bioFILM PA™ in assisting physicians in selecting antibiotics that will give the patient the best opportunity to regain healthy lung function," says Dr. Bhavin Rawal, Product Manager for bioFILM PA™.

About bioFILM PA™

bioFILM PA™ is the world's first biofilm susceptibility test that also provides guidance to doctors on the selection of combination antibiotics. These attributes recognize and address the fact that biofilm infections, like CF lung disease, pneumonia and other respiratory infections are not adequately treated with current technologies.

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information